<p>BioLife Solutions, Inc.（納斯達克代碼：BLFS - 獲取免費報告）在覆蓋該股票的六家券商中獲得了 “買入” 的共識評級，MarketBeat 報道。六位投資分析師對該股票給予了買入推薦。在過去一年中，給予該股票評級的券商的平均一年目標價為 31.17 美元。</p>
<p>獲取 <strong>BioLife Solutions</strong> 的提醒：</p>
<ul>
<li>現在值得投資的最佳生物科技股票</li>
</ul>
<p>幾家券商最近對 BLFS 進行了評論。華爾街禪在週三的研究報告中將 BioLife Solutions 的評級從 “持有” 下調至 “賣出”。HC Wainwright 在 5 月 13 日的報告中重申了 “買入” 評級，並設定了 BioLife Solutions 股票的 30.00 美元目標價。</p>
<p><strong>閲讀我們關於 BioLife Solutions 的最新股票分析</strong></p>
<h2>BioLife Solutions 股票表現</h2>
<ul>
<li>3 只小型醫療股今天正在影響市場</li>
</ul>
<p>納斯達克 BLFS 的股票在週五開盤價為 22.10 美元。該公司的流動比率為 2.78，速動比率為 1.78，債務股本比率為 0.03。BioLife Solutions 的 12 個月低點為 18.70 美元，12 個月高點為 29.55 美元。該股票的 50 日移動平均線為 23.27 美元，200 日移動平均線為 25.24 美元。該公司的市值為 10.5 億美元，市盈率為-20.85，貝塔值為 2.01。</p>
<p>BioLife Solutions（納斯達克代碼：BLFS - 獲取免費報告）最近一次發佈財報是在 5 月 8 日，醫療設備提供商報告本季度每股收益為 0.04 美元，超出市場共識預期的-0.03 美元，超出幅度為 0.07 美元。BioLife Solutions 的股本回報率為-6.61%，淨利潤率為-38.98%。該公司本季度的收入為 2394 萬美元，而市場共識預期為 2222 萬美元。整體來看，股票研究分析師預測 BioLife Solutions 本年度將發佈-0.3 美元的每股收益。</p>
<h2>內部買賣情況</h2>
<p>在其他 BioLife Solutions 的新聞中，首席營銷官 Todd Berard 在 3 月 11 日的交易中出售了 1577 股 BioLife Solutions 股票。該股票以平均價格 25.00 美元出售，總價值為 39425.00 美元。交易完成後，首席營銷官現在直接持有公司 104961 股股票，價值 2624025 美元。此次交易使其持股減少了 1.48%。該出售在與證券交易委員會的法律文件中披露，相關信息可在 SEC 網站上找到。此外，首席財務官 Troy Wichterman 在 3 月 11 日的交易中出售了 4151 股 BioLife Solutions 股票。該股票以平均價格 25.00 美元出售，總價值為 103775.00 美元。交易完成後，首席財務官現在直接持有公司 116809 股股票，價值 2920225 美元。這代表其持股減少了 3.43%。該出售的披露信息可以在這裏找到。在過去的九十天裏，內部人士出售了 71696 股公司股票，價值 1665094 美元。內部人士持有公司 2.20% 的股份。</p>
<h2>對 BioLife Solutions 的對沖基金看法</h2>
<p>對沖基金和其他機構投資者最近增加或減少了對該股票的持股。Steward Partners Investment Advisory LLC 在第四季度獲得了 BioLife Solutions 的新頭寸，價值 26000 美元。Point72 Asia Singapore Pte. Ltd. 在第四季度獲得了 BioLife Solutions 的新頭寸，價值 31000 美元。懷俄明州在第一季度將其在 BioLife Solutions 的持股增加了 353.1%。懷俄明州現在持有 1912 股該醫療設備提供商的股票，價值 44000 美元，此前在上一季度增加了 1490 股。US Bancorp DE 在第一季度將其在 BioLife Solutions 的持股增加了 243.7%。US Bancorp DE 現在持有 2155 股該醫療設備提供商的股票，價值 49000 美元，此前在上一季度增加了 1528 股。最後，1620 Investment Advisors Inc. 在第四季度將其在 BioLife Solutions 的持股增加了 41.7%。1620 Investment Advisors Inc. 現在持有 2295 股該醫療設備提供商的股票，價值 60000 美元，此前在上一季度增加了 675 股。93.24% 的股票由機構投資者和對沖基金持有。</p>
<h2>BioLife Solutions 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>BioLife Solutions, Inc. 在美國、歐洲、中東、非洲及國際市場開發、製造和銷售用於細胞和基因治療（CGT）行業的生物生產工具和服務。該公司的產品用於生物基療法的基礎和應用研究以及商業製造。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 BioLife Solutions</li>
<li>3 只證明仍然必不可少的雜貨股票</li>
<li>Joby 股票的動盪：最近下跌的原因是什麼？</li>
<li>深入分析買賣差價</li>
<li>為什麼嘉年華可能是終極非科技增長股票</li>
<li>複利及其在投資中的重要性</li>
<li>超級微型計算機股票在沙特訂單中開闢新路徑</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkxGUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkxGUw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元於 BioLife Solutions 嗎？</h2>
<p>在考慮 BioLife Solutions 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前進行購買……而 BioLife Solutions 並不在名單上。</p>
<p>雖然 BioLife Solutions 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

BLFS

<p>BioLife Solutions, Inc.（納斯達克代碼：BLFS）獲得了六家券商的一致 “買入” 評級。平均目標價格為 31.17 美元。儘管 Wall Street Zen 將其評級下調至 “賣出”，但 HC Wainwright 仍維持 “買入” 評級，目標價為 30 美元。該股票開盤價為 22.10 美元，市值為 10.5 億美元。最近的財報顯示每股收益為 0.04 美元，超出預期。內部人士最近出售了部分股份，機構投資者持有 93.24% 的股份。BioLife 為細胞和基因治療行業開發生物生產工具</p>

<p>BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) has been given a consensus rating of &#34;Buy&#34; by the six brokerages that are covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $31.17.</p>
<div class="lb-trans"><p>BioLife Solutions, Inc.（納斯達克代碼：BLFS - 獲取免費報告）在覆蓋該股票的六家券商中獲得了 “買入” 的共識評級，MarketBeat 報道。六位投資分析師對該股票給予了買入推薦。在過去一年中，給予該股票評級的券商的平均一年目標價為 31.17 美元。</p>
</div><p>Get <strong>BioLife Solutions</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>BioLife Solutions</strong> 的提醒：</p>
</div><ul>
<li>Best Biotech Stocks to Invest in Now</li>
</ul>
<div class="lb-trans"><ul>
<li>現在值得投資的最佳生物科技股票</li>
</ul>
</div><p>Several brokerages have recently commented on BLFS. Wall Street Zen downgraded BioLife Solutions from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Wednesday. HC Wainwright reissued a &#34;buy&#34; rating and set a $30.00 price target on shares of BioLife Solutions in a report on Tuesday, May 13th.</p>
<div class="lb-trans"><p>幾家券商最近對 BLFS 進行了評論。華爾街禪在週三的研究報告中將 BioLife Solutions 的評級從 “持有” 下調至 “賣出”。HC Wainwright 在 5 月 13 日的報告中重申了 “買入” 評級，並設定了 BioLife Solutions 股票的 30.00 美元目標價。</p>
</div><p><strong>Read Our Latest Stock Analysis on BioLife Solutions</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 BioLife Solutions 的最新股票分析</strong></p>
</div><h2>BioLife Solutions Stock Performance</h2>
<div class="lb-trans"><h2>BioLife Solutions 股票表現</h2>
</div><ul>
<li>3 Small-Cap Medical Stocks Moving Markets Today</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只小型醫療股今天正在影響市場</li>
</ul>
</div><p>Shares of NASDAQ BLFS opened at $22.10 on Friday. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. BioLife Solutions has a 12 month low of $18.70 and a 12 month high of $29.55. The stock has a 50 day moving average of $23.27 and a 200-day moving average of $25.24. The company has a market capitalization of $1.05 billion, a P/E ratio of -20.85 and a beta of 2.01.</p>
<div class="lb-trans"><p>納斯達克 BLFS 的股票在週五開盤價為 22.10 美元。該公司的流動比率為 2.78，速動比率為 1.78，債務股本比率為 0.03。BioLife Solutions 的 12 個月低點為 18.70 美元，12 個月高點為 29.55 美元。該股票的 50 日移動平均線為 23.27 美元，200 日移動平均線為 25.24 美元。該公司的市值為 10.5 億美元，市盈率為-20.85，貝塔值為 2.01。</p>
</div><p>BioLife Solutions (NASDAQ:BLFS - Get Free Report) last issued its earnings results on Thursday, May 8th. The medical equipment provider reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.07. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The company had revenue of $23.94 million during the quarter, compared to the consensus estimate of $22.22 million. As a group, equities research analysts predict that BioLife Solutions will post -0.3 EPS for the current year.</p>
<div class="lb-trans"><p>BioLife Solutions（納斯達克代碼：BLFS - 獲取免費報告）最近一次發佈財報是在 5 月 8 日，醫療設備提供商報告本季度每股收益為 0.04 美元，超出市場共識預期的-0.03 美元，超出幅度為 0.07 美元。BioLife Solutions 的股本回報率為-6.61%，淨利潤率為-38.98%。該公司本季度的收入為 2394 萬美元，而市場共識預期為 2222 萬美元。整體來看，股票研究分析師預測 BioLife Solutions 本年度將發佈-0.3 美元的每股收益。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣情況</h2>
</div><p>In other BioLife Solutions news, CMO Todd Berard sold 1,577 shares of BioLife Solutions stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total value of $39,425.00. Following the completion of the transaction, the chief marketing officer now directly owns 104,961 shares of the company's stock, valued at $2,624,025. The trade was a 1.48% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, CFO Troy Wichterman sold 4,151 shares of BioLife Solutions stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total value of $103,775.00. Following the completion of the transaction, the chief financial officer now directly owns 116,809 shares of the company's stock, valued at $2,920,225. This represents a 3.43% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 71,696 shares of company stock valued at $1,665,094. Insiders own 2.20% of the company's stock.</p>
<div class="lb-trans"><p>在其他 BioLife Solutions 的新聞中，首席營銷官 Todd Berard 在 3 月 11 日的交易中出售了 1577 股 BioLife Solutions 股票。該股票以平均價格 25.00 美元出售，總價值為 39425.00 美元。交易完成後，首席營銷官現在直接持有公司 104961 股股票，價值 2624025 美元。此次交易使其持股減少了 1.48%。該出售在與證券交易委員會的法律文件中披露，相關信息可在 SEC 網站上找到。此外，首席財務官 Troy Wichterman 在 3 月 11 日的交易中出售了 4151 股 BioLife Solutions 股票。該股票以平均價格 25.00 美元出售，總價值為 103775.00 美元。交易完成後，首席財務官現在直接持有公司 116809 股股票，價值 2920225 美元。這代表其持股減少了 3.43%。該出售的披露信息可以在這裏找到。在過去的九十天裏，內部人士出售了 71696 股公司股票，價值 1665094 美元。內部人士持有公司 2.20% 的股份。</p>
</div><h2>Hedge Funds Weigh In On BioLife Solutions</h2>
<div class="lb-trans"><h2>對 BioLife Solutions 的對沖基金看法</h2>
</div><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Steward Partners Investment Advisory LLC acquired a new position in BioLife Solutions in the 4th quarter valued at $26,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in BioLife Solutions in the 4th quarter valued at $31,000. State of Wyoming raised its holdings in BioLife Solutions by 353.1% in the 1st quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider's stock valued at $44,000 after acquiring an additional 1,490 shares in the last quarter. US Bancorp DE raised its holdings in BioLife Solutions by 243.7% in the 1st quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider's stock valued at $49,000 after acquiring an additional 1,528 shares in the last quarter. Finally, 1620 Investment Advisors Inc. raised its holdings in BioLife Solutions by 41.7% in the 4th quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock valued at $60,000 after acquiring an additional 675 shares in the last quarter. 93.24% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>對沖基金和其他機構投資者最近增加或減少了對該股票的持股。Steward Partners Investment Advisory LLC 在第四季度獲得了 BioLife Solutions 的新頭寸，價值 26000 美元。Point72 Asia Singapore Pte. Ltd. 在第四季度獲得了 BioLife Solutions 的新頭寸，價值 31000 美元。懷俄明州在第一季度將其在 BioLife Solutions 的持股增加了 353.1%。懷俄明州現在持有 1912 股該醫療設備提供商的股票，價值 44000 美元，此前在上一季度增加了 1490 股。US Bancorp DE 在第一季度將其在 BioLife Solutions 的持股增加了 243.7%。US Bancorp DE 現在持有 2155 股該醫療設備提供商的股票，價值 49000 美元，此前在上一季度增加了 1528 股。最後，1620 Investment Advisors Inc. 在第四季度將其在 BioLife Solutions 的持股增加了 41.7%。1620 Investment Advisors Inc. 現在持有 2295 股該醫療設備提供商的股票，價值 60000 美元，此前在上一季度增加了 675 股。93.24% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>BioLife Solutions Company Profile</h2>
<div class="lb-trans"><h2>BioLife Solutions 公司簡介</h2>
</div><p>(Get Free Report</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.</p>
<div class="lb-trans"><p>BioLife Solutions, Inc. 在美國、歐洲、中東、非洲及國際市場開發、製造和銷售用於細胞和基因治療（CGT）行業的生物生產工具和服務。該公司的產品用於生物基療法的基礎和應用研究以及商業製造。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than BioLife Solutions</li>
<li>3 Grocery Stocks That Are Proving They Are Still Essential</li>
<li>Turbulence for Joby Shares: What's Behind the Recent Dip?</li>
<li>A Deeper Look at Bid-Ask Spreads</li>
<li>Why Carnival Could Be the Ultimate Non-Tech Growth Stock</li>
<li>Compound Interest and Why It Matters When Investing</li>
<li>Super Micro Computer Stock Clears New Path Higher on Saudi Orders</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 BioLife Solutions</li>
<li>3 只證明仍然必不可少的雜貨股票</li>
<li>Joby 股票的動盪：最近下跌的原因是什麼？</li>
<li>深入分析買賣差價</li>
<li>為什麼嘉年華可能是終極非科技增長股票</li>
<li>複利及其在投資中的重要性</li>
<li>超級微型計算機股票在沙特訂單中開闢新路徑</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkxGUw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=BLFS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in BioLife Solutions Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元於 BioLife Solutions 嗎？</h2>
</div><p>Before you consider BioLife Solutions, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 BioLife Solutions 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioLife Solutions wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前進行購買……而 BioLife Solutions 並不在名單上。</p>
</div><p>While BioLife Solutions currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 BioLife Solutions 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

BioLife Solutions, Inc.（納斯達克股票代碼：BLFS）被券商平均推薦為 “買入”